Alnylam Pharmaceuticals
ALNY
#612
Rank
โ‚ฌ34.55 B
Marketcap
258,95ย โ‚ฌ
Share price
-1.59%
Change (1 day)
15.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): 1,50ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is 1,54ย โ‚ฌ. In 2023 the company made an earnings per share (EPS) of -3,01ย โ‚ฌ an increase over its 2022 EPS that were of -7,92ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)1,50ย โ‚ฌ
2023-3,01ย โ‚ฌ-62%
2022-7,92ย โ‚ฌ29.03%
2021-6,14ย โ‚ฌ-3.36%
2020-6,35ย โ‚ฌ-8.48%
2019-6,94ย โ‚ฌ7.67%
2018-6,45ย โ‚ฌ39.74%
2017-4,61ย โ‚ฌ12.94%
2016-4,09ย โ‚ฌ38.84%
2015-2,94ย โ‚ฌ-32.88%
2014-4,38ย โ‚ฌ259.44%
2013-1,22ย โ‚ฌ-31.25%
2012-1,77ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
6,14ย โ‚ฌ 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
1,76ย โ‚ฌ 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
36,78ย โ‚ฌ 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-2,34ย โ‚ฌ-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-0,62ย โ‚ฌ-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-0,20ย โ‚ฌ-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
1,06ย โ‚ฌ-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
0,30ย โ‚ฌ-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA